drugset
drugset / Trial / NCT03758716

An Open-Labeled Exploratory Study to Evaluate Safety and Efficacy of FB825 in Adults With Atopic Dermatitis

NCT03758716 ↗

Phase 2 Completed 12 enrolled Fountain Biopharma Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the Safety and Efficacy of FB825 in Adults with Atopic Dermatitis

Timeline

Start
2017-07-03
Primary completion
2019-01-28
Completion
2019-09-19

Drugs

EvaluationDrugModalityDoseRoute
Subject FB825 Unknown — Intravenous

Indications

atopic eczema